Typbar-TCV Typhoid Conjugate Vaccine

22:42 EST 23rd November 2017 | BioPortfolio

Typbar-TCV™, world's first clinically proven typhoid conjugate vaccine for infants 6 months & older and Adults.

The new vaccine brings hope to millions of adults and infants older than 6 months, by protecting against typhoid fever caused by Salmonella typhi, a highly virulent and invasive enteric bacterium.

Typbar®, the first vaccine in India to get a WHO-GMP Certificate, is a highly purified VI Capsular Polysaccharide New Generation Typhoid vaccine. Typbar® would also be the world’s first vegetarian or nonbovine typhoid vaccine. Bharat Biotech is the largest primary manufactures of typhoid vaccine in the country. The Company dedicated the vaccine to Dr. John R. Robbins, Father of Polysaccharide vaccines.

Typbar-TCV - typhoid conjugate vaccine

Typbar product information -

Quick Search

review and buy Typbar-TCV Typhoid Conjugate Vaccine market research data and corporate reports here